Genomic & Proteomic Analysis of Docetaxel & Capecitabine as Primary Chemo for Stage II-III Breast Cancer
Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the efficacy & toxicity of combined
docetaxel & capecitabine as primary chemo for subjects w/ stage II-III breast cancer.